Immuno-oncology is reshaping cancer treatment – but the preclinical models used to develop these therapies are evolving as well, towards faster and affordable NAMs solutions. Inovotion’s CAM (Chorioallantoic Membrane) model has been scientifically validated as a versatile tool to assess IO treatments, including checkpoint inhibitors, CAR-T therapies, and anti-tumor vaccines.

In this 2nd post of our scientific series, we highlight recent research demonstrating how the CAM model offers a physiologically immune-reactive environment to evaluate immunotherapies in vivo:

1. In Ovo Model in Tumor Immunology Research
“In ovo model in cancer research and tumor immunology “
Miebach L, Berner J, Bekeschus S. (2022). Front Immunol.
Pubmed: https://pubmed.ncbi.nlm.nih.gov/36248802/

2. Checkpoint Inhibitors in the CAM Model
“PD-1/PD-L1 Checkpoint Inhibitors Are Active in the Chicken Embryo Model and Show Antitumor Efficacy In Ovo “
Wang Y et al. (2022). Cancers (Basel)
Pubmed: https://pubmed.ncbi.nlm.nih.gov/35804865/

3. The CAM as an Immune-Based Study Platform
“The Chicken Embryo Model: A Novel and Relevant Model for Immune-Based Studies “
Garcia P et al. (2021). Front Immunol.
Pubmed: https://pubmed.ncbi.nlm.nih.gov/34868080/

4. Targeting HSP110 with Nanofitins – In Ovo Validation
“Nanofitins targeting heat shock protein 110: An innovative immunotherapeutic modality in cancer “
Marcion G et al. (2021). Int J Cancer
Pubmed: https://pubmed.ncbi.nlm.nih.gov/33506516/

5. Poster at AACR 2024 – CAR-T Cell Therapy in CAM Model
“An innovative in vivo model for CAR-T cell therapy development: Tolerability and efficacy of CD19-targeting CAR-T cells on human lymphoma using the chicken CAM assay “
Wang Y et al., Inovotion & Allogenica

6. Poster at AACR 2023  – Anti-Tumor Vaccine STC-1010 Evaluation
“An Innovative In Vivo Model for Anti-tumor Vaccine Development: Action Mode Exploitation and Efficacy Evaluation of A New Antitumor Vaccine STC-1010 on Human Colorectal Adenocarcinoma Using Chicken CAM Assay”
Wang Y et al., Inovotion & Brenus – AACR 2023

7. Poster at EACR 2024 – CAM Assay as a Platform for IO Drug Development
“CAM assay: An alternative, 3Rs-compliant, in vivo model for the development of immunotherapy for cancer “
Wang Y et al., Inovotion, Brenus, Allogenica – EACR 2024
Download: https://www.inovotion.com/news-and-events/download-our-poster-2-at-eacr-2025-2

These studies collectively show that Inovotion’s NAMs CAM model offers real-time immune system interactions, high tumor engraftment success, and translational relevance, making it an invaluable platform to de-risk and accelerate immuno-oncology development.

Stay tuned for our next post in this scientific series on: Mechanisms of Action.

Follow us to discover how leading biotech and pharma companies use the CAM model to accelerate and de-risk their oncology pipelines – with robust, reproducible data.
Learn more about our platform: https://www.inovotion.com